US Ecology/ US91734M1036 /
29.04.2022 00:00:00 | Diff. - | Volumen | Geld- | Brief- | Tageshoch | Tagestief |
---|---|---|---|---|---|---|
47,9900USD | - | 1,06 Mio. Umsatz: - |
-Geld Vol: - | -Brief Vol: - | 48,0100 | 47,9850 |
GlobeNewswire
14:01
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Pric...
GlobeNewswire
14:01
BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation ...
GlobeNewswire
14:01
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for it...
GlobeNewswire
14:00
Kairous Acquisition Corp. Limited Announces Additional Contribution to Trust Account to Extend Perio...
GlobeNewswire
14:00
Infinera to Participate in J.P. Morgan’s 2024 Global Technology, Media and Communications Conference
GlobeNewswire
14:00
Scorpius Holdings Announces Major Expansion in San Antonio with New State-of-the-Art Storage and Tes...
GlobeNewswire
14:00
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO ...
GlobeNewswire
14:00
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau)...
GlobeNewswire
14:00
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile...
GlobeNewswire
14:00
PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors
GlobeNewswire
14:00
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foo...
GlobeNewswire
14:00
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
14:00
Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI...
GlobeNewswire
14:00
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Adva...
- Erste Seite
- Zurück
- 1
- 2
- 3
- 4
- Weiter
- Letzte Seite